Ravi Madan/X
Feb 13, 2025, 07:54
Ravi Madan: The true value of PFS endpoints in prostate cancer
Ravi Madan, Clinical researcher at the National Cancer Institute, shared a post on X about a paper he co-authored with colleagues published in Nature Reviews Urology:
“As ASCO GU25 approaches worth considering again the true value of Progression Free Survival (PFS) endpoints in prostate cancer.”
“Progression-free survival end points in prostate cancer: are we truly making progress”
Authors: Ravi Madan, Edwin Posadas and Richard Lee.
More posts featuring Ravi Madan.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 13, 2025, 14:26
Mar 13, 2025, 10:43
Mar 13, 2025, 10:14
Mar 13, 2025, 10:06
Mar 13, 2025, 09:32
Mar 13, 2025, 09:10
Mar 13, 2025, 09:07
Mar 13, 2025, 08:55
Mar 13, 2025, 08:44